MLN4924通过促进Act1降解和阻断Act1介导的mRNA稳定性来缓解自身免疫性心肌炎
Zuli Jiang1, Zhuolun Li2, Youming Chen1
1Department of Clinical Laboratory, Key Laboratory of Henan province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
International immunopharmacology
|July 22, 2024
概括
作为NEDD8激活酶的抑制剂,MLN4924通过减少炎症来有效治疗自身免疫性心肌炎. 它破坏了关键蛋白相互作用,降低了促炎因素,改善了心脏组织的健康.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 交叉蛋白-17A (IL-17A) 暴露可能导致自身免疫性心肌炎.
- 作为NEDD8激活酶 (NAE) 抑制剂的MLN4924,显示出抗炎作用的潜力.
- 在IL-17A介导的自身免疫性心肌炎中,MLN4924的疗效尚不清楚.
研究的目的:
- 研究MLN4924对IL-17A诱导的自身免疫性心肌炎的治疗作用.
- 在这种疾病模型中阐明MLN4924作用的潜在分子机制.
主要方法:
- 在体内建立了一个实验性自身免疫性心肌炎 (EAM) 模型.
- 通过组织病理学评估心脏炎症,并测量细胞因子/化学因子水平 (ELISA,RT-qPCR).
- 利用共免疫沉 (Co-IP) 和RNA免疫沉 (RIP) 来分析分子相互作用.
主要成果:
- 在EAM中,MLN4924治疗减轻了IL-17A诱导的炎症,减少了免疫细胞透和组织纤维化.
- MLN4924降低了IL-1β,IL-6,TNF-α和MCP-1的血清水平.
- 从机制上来说,MLN4924促进了Act1的泛化和降解,破坏了IL-17R/Act1复合体的形成,并损害了Act1介导的mRNA稳定性.
结论:
- MLN4924有效地缓解了自身免疫性心肌炎的症状.
- 该药物通过破坏IL-17R/Act1相互作用而起作用,从而减少促炎因子的表达.
- MLN4924为IL-17A驱动的炎症性心脏病提供了一个潜在的治疗策略.
更多相关视频
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
7.6K
11:07A Murine Model of Myocardial Ischemia-reperfusion Injury through Ligation of the Left Anterior Descending Artery
Published on: April 10, 2014
39.5K
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414